GSK’s Stiefel Laboratories Acquires Welichem Biotech’s Mid-Stage Psoriasis and Atopic Dermatitis Drug
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 6 (Table of Contents)
Published: 7 Jun-2012
DOI: 10.3833/pdr.v2012.i6.1749 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
GlaxoSmithKline’s Stiefel Laboratories has agreed to acquire worldwide development and commercialisation rights to Welichem Biotech’s WBI-1001, a topical anti-inflammatory agent in Phase II development for psoriasis and atopic dermatitis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS